GLENMARK PHARMA Results Analysis-Q1FY27

$GLENMARK Financial performance and key Operating Metrics (Consolidated) : Operating Revenue for Q1FY27 is Rs. 4,018 Crs., 23.1% growth YoY, Total Income is Rs. 4,084 Crs., 24.11% growth YoY, Gross Profit is Rs. 2,838 Crs., 26.22% growth YoY, EBITDA is Rs. 871 Crs., 43.43% growth YoY, EBITDA Margin is 21.31% improved by 287 basis points YoY, PBT Rs. 643 Crs., 573.14% growth YoY (due to exceptional loss in Q1FY26), PAT Rs. 483 Crs. 927.95% growth YoY. On QoQ basis Operating Revenue is up by 5.78%, Total Income is also up by 5.11%, Gross Profit is up by 10.46%, EBITDA is up by 13.14%, PBT is up by 16.13% and PAT is also up by 16.3%. India formulations: sustained outperformance, oncology ramp, and differentiated respiratory : India formulations sales: Rs 14,321 million, up 15.5% YoY. India consumer care (GCC): strong primary growth and brand-led acceleration : Q1 primary sales: Rs 1,558 million, up 28% YoY, Candid franchise grew “upwards of 30% across all its variants.” North America: recovery driven by respiratory franchise; injectables building blocks in place, Europe: near-term growth muted; strategic pivot toward branded respiratory/dermatology : Europe revenue: Rs 7,472 million, up 11.9% YoY (management still called overall growth “muted” vs prior years’ faster pace). Emerging Markets & APAC: strong growth, Ryaltris expansion, and partner-led launches : Emerging Markets revenue: Rs 7,304 million, up 27.7% YoY. Oncology specialty build is a key strategic investment, most major litigations are already provided for.